- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00294177
Conformation of Beta Human Chorionic Gonadotropin During Chemotherapy for Choriocarcinoma
Conformation of Beta Human Chorionic Gonadotropin During Chemotherapy for Persistent Gestational Trophoblastic Tumors Using Atomic Force Microscopy and Dual Polarisation Interferometry
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The conformational change of human chorionic gonadotropin beta (hCG beta) during chemotherapy for gestational trophoblastic disease and its clinical meaning have not been well understood. In this study we will use atomic force microscopy and dual polarisation interferometry to measure the dimensions and conformational change of beta human chorionic gonadotropin during chemotherapy for persistent gestational trophoblastic tumors.
Gestational trophoblastic disease comprises a spectrum of diseases with different propensity for local invasion and metastasis, that is, partial and complete hydatidiform mole, choriocarcinoma, and placental site trophoblastic tumor. Persistent trophoblastic disease may develop both from partial and complete moles. All trophoblastic tumors produce human chorionic gonadotropin (hCG), and monitoring of therapy is largely based on the determination of hCG in serum. The more malignant forms also express excessive amounts of hCG beta, and simultaneous determination of hCG and hCG beta can be used to differentiate between molar disease and trophoblastic cancer, which is associated with a proportion of hCG beta exceeding 5%. Over glycosylated hCG has also been reported to be a characteristic of trophoblastic cancer, but its clinical utility remains to be established. The hCG beta level in serum is also used to evaluate prognosis with not only very high but also very low levels in relation to tumor burden being indicative of adverse prognosis. Because of that: 1). more malignant forms also express excessive amounts of hCG beta; 2). the half-life of hCG beta is longer than that of hCG; 3). the hCG beta /hCG ratio will increase when the levels decrease after successful therapy; and 4). the ratio has been found to increase during development of therapy-resistant disease, monitoring of gestational trophoblastic disease usually relies on human chorionic gonadotropin beta measurement. Treatment of choriocarcinoma is most often monitored by serial assay of hCG beta in serum until the levels are undetectable, and simultaneous determination of hCG beta can sometimes reveal a relapse earlier than hCG. Therefore, measurement of hCG beta is important in treatment of gestational trophoblastic tumors.
Human choriogonadotropin belongs to a family of heterodimeric glycoprotein hormones which are comprised of two noncovalently bonded subunits with four N-linked carbohydrates. During chemotherapy, the hCG beta molecules can be degraded. A study has been reported by crystallographic analysis by which they found that crystals of deglycosylated human chorionic gonadotropin has a hexagonal bipyramidal structure using a method of vapor diffusion against ammonium sulfate. Previously, conformation of the hCG molecule has rarely been studied. By chemical method, over glycosylated hCG has been reported to be a characteristic of trophoblastic cancer, but its clinical utility remains to be established. Photoelectric method is a newly developed method to study the conformation of the protein or glycoprotein molecules. As yet, there is no report about the conformation of hCG serial studies. Gestational trophoblastic tumor as well as other gynecological cancers often underwent antitumor chemotherapy and monitor by tumor markers. During the antineoplastic chemotherapies, the conformational change of tumor markers, including hCG beta in persistent gestational trophoblastic tumor for cancer and its clinical meaning has only been rarely studied. Up to the present time, it is still not well understood whether a conformational change or reduced stability of the heterodimer may occur during chemotherapy.
In this study we will use an atomic force microscopy (AFM) to probe the surface nanostructure of beta human chorionic gonadotropin. The conformational change of the beta human chorionic gonadotropin which is secreted by persistent gestational trophoblastic tumors during chemotherapy will be studied. We will also want to directly visualize a single molecular structure of beta human chorionic gonadotropin, and quantitative measurements of the dimensions of the glycoprotein will be provided. The average height calculated for each hCG beta particle will be measured and compared subsequently during chemotherapy. Moreover, a experiment using dual polarization interferometric (DPI) as a biosensor will also be performed, and the average monolayer thickness value will also be calculated. To investigate further the surface ultrastructure of a hCG beta molecule, a hCG beta sample at very low concentration will be scanned in vacuum by AFM. The higher-resolution images will clearly reveal the shape of hCG beta molecules. In addition, phase images of hCG beta molecules will be captured simultaneously with their height images, and the lateral dimensions of the shape of hCG beta molecules will then be measured and calculated. The average values calculated for the outside diameter and pore diameter will thus be obtained. This study will represent the first direct characterization of the surface ultrastructure of the hCG beta molecule at a nanometer scale. The physical measurements of the outer diameter, pore diameter, and protomer diameter in the hCG beta by AFM and DPI may suggest how to recognize hCG beta molecules, which constitute an important tumor marker during chemotherapy for persistent gestational trophoblastic tumors. Unraveling the molecular structure and measuring the dimensions of hCG beta may provide new directions for future application in clinical hCG beta sensor chips. In can also be likely that the dimensional change of hCG beta molecules may also have some clinical implications for persistent gestational trophoblastic tumors.
Study Type
Enrollment
Contacts and Locations
Study Contact
- Name: Ruey-Jien Chen, MD, PhD
- Phone Number: 5158 886-2-23123456
- Email: rjchen@ha.mc.ntu.edu.tw
Study Locations
-
-
-
Taipei, Taiwan, 100
- National Taiwan University Hospital Department of Obstetrics and Gynecology
-
Contact:
- Ruey-Jien Chen, MD, PhD
- Phone Number: 5158 886-2-2312-3456
- Email: rjchen@ha.c.ntu.edu.tw
-
Principal Investigator:
- Ruey-Jien Chen, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clinical diagnosis of trophoblastic neoplasms
- Willing to be collected for the urine and 2 ml blood samples
Exclusion Criteria:
- Unwilling to be collected for the collect urine or 2ml blood sample
Study Plan
How is the study designed?
Design Details
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Ruey-Jien Chen, Department or Obstetrics and Gynecology, National Taiwan university Hospital
Publications and helpful links
General Publications
- Birken S, Armstrong EG, Kolks MA, Cole LA, Agosto GM, Krichevsky A, Vaitukaitis JL, Canfield RE. Structure of the human chorionic gonadotropin beta-subunit fragment from pregnancy urine. Endocrinology. 1988 Jul;123(1):572-83. doi: 10.1210/endo-123-1-572.
- Swann MJ, Peel LL, Carrington S, Freeman NJ. Dual-polarization interferometry: an analytical technique to measure changes in protein structure in real time, to determine the stoichiometry of binding events, and to differentiate between specific and nonspecific interactions. Anal Biochem. 2004 Jun 15;329(2):190-8. doi: 10.1016/j.ab.2004.02.019.
- Czajkowsky DM, Hotze EM, Shao Z, Tweten RK. Vertical collapse of a cytolysin prepore moves its transmembrane beta-hairpins to the membrane. EMBO J. 2004 Aug 18;23(16):3206-15. doi: 10.1038/sj.emboj.7600350. Epub 2004 Aug 5.
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 9561702010
- Taiwan NSC 94WFA0101857
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Trophoblastic Neoplasms
-
Tracon Pharmaceuticals Inc.TerminatedGestational Trophoblastic Neoplasia | Choriocarcinoma | Placental Site Trophoblastic Tumor | Epithelioid Trophoblastic TumorUnited States
-
xiang yangRecruitingGestational Trophoblastic Tumor | Gestational Trophoblastic Neoplasia | Choriocarcinoma | Stage I Gestational Trophoblastic Tumor | Stage II Gestational Trophoblastic Tumor | Stage III Gestational Trophoblastic Tumor | Invasive MoleChina
-
GOG FoundationNational Cancer Institute (NCI)CompletedHydatidiform Mole | Choriocarcinoma | FIGO Stage I Gestational Trophoblastic Tumor | FIGO Stage II Gestational Trophoblastic Tumor | FIGO Stage III Gestational Trophoblastic TumorUnited States, Korea, Republic of, Canada, Japan, United Kingdom
-
Ding MaShandong University; Huazhong University of Science and Technology; Zhejiang...UnknownGestational Trophoblastic Tumor | Gestational Trophoblastic Neoplasia | Gestational Trophoblastic Disease | Gestational Trophoblastic NeoplasmsChina
-
Gynecologic Oncology GroupNational Cancer Institute (NCI); Eastern Cooperative Oncology GroupCompletedHydatidiform Mole | Good Prognosis Metastatic Gestational Trophoblastic Tumor | Non-Metastatic Gestational Trophoblastic Tumor | Uterine Corpus ChoriocarcinomaUnited States
-
Weiguo LvShandong University; Huazhong University of Science and Technology; First Affiliated...RecruitingGestational Trophoblastic NeoplasmsChina
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedGestational Trophoblastic TumorUnited States, Norway
-
Brigham and Women's HospitalUniversidade Federal do Rio de Janeiro; Maternidade Escola da Universidade... and other collaboratorsRecruitingGestational Trophoblastic Neoplasia | Molar Pregnancy | Gestational Trophoblastic Tumor, Non-MetastaticBrazil
-
Hospices Civils de LyonCompletedGestational Trophoblastic Neoplasias (GTN)France
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)TerminatedGestational Trophoblastic TumorUnited States
Clinical Trials on atomic force microscopy
-
Fondazione Policlinico Universitario Agostino Gemelli...Not yet recruiting
-
Connecticut Children's Medical CenterThe Hospital for Sick ChildrenRecruitingPediatric CancerUnited States
-
University of Wisconsin, MadisonCompleted
-
The Hospital for Sick ChildrenUniversity of Alabama at Birmingham; Queen's UniversityCompletedPediatric Multiple SclerosisCanada
-
Taipei Medical University Shuang Ho HospitalRecruitingCaregivers With Toddler Receiving Early InterventionTaiwan
-
VA Office of Research and DevelopmentUniversity of IowaCompleted
-
Johns Hopkins UniversityAmerican Society for Gastrointestinal Endoscopy; Pentax Medical CorporationCompletedBarrett's Esophagus, Esophageal Intraepithelial NeoplasiaUnited States, Germany
-
Acutus MedicalCompletedTypical Atrial FlutterBelgium, United States, United Kingdom
-
University of BaghdadCompletedGingival Diseases | Tooth Diseases | Root Resorption | Orthodontic Appliance Complication | Orthodontic Pathological Resorption of External Root | Tooth PlaqueIraq
-
Zimmer BiometTerminatedIntracapsular Proximal Femur Fracture | Garden Grade I Subcapital Fracture of Femoral Neck | Garden Grade II Subcapital Fracture of Femoral NeckUnited States